ARF6 and neoplasm: These findings strongly suggest that targeting the ARF6-AMAP1 pathway partially alleviates the immune evasion of KPC tumor cells, and the combination of the inhibition of this pathway with anti-PD-1 antibody therapy enhances the therapeutic effect.